Composition
Cap 12.5 mg/25 mg/50 mg: Sunitinib 12.5 mg/25 mg/50 mg.
Indications & Dosage
Treatment of advanced or metastatic renal cell carcinoma. Treatment of unresectable or metastatic gastrointestinal stromal tumours (GIST). Treatment of unresectable or metastatic malignant gastrointestinal stromal tumours, after failure of imatinib, Treatment of advanced or metastatic renal cell carcinoma: Adult: 50 mg once daily for 4 weeks, followed by a 2-week treatment-free period to complete 6-week cycle, adjusted in steps of 12.5 mg, doses adjusted according to tolerability; usual dose 25-75 mg daily. Treatment of unresectable or metastatic pancreatic Neuroendocrine tumours: Adult: 37.5 mg once daily without treatment-free period; adjusted in steps of 12.5 mg, doses adjusted according to tolerability; max. 50 mg per day.
Precautions
Risk of fatal pulmonary haemorrhage, hypertension. Perform complete blood count prior to treatment. Pre-existing cardiac disease; discontinue if congestive heart failure develops, electrolytes disturbances, monitor for thyroid dysfunction and pancreatitis, increased risk of bleeding, susceptibility to QT-interval prolongation
Interactions
Rifampicin, phenobarbital, phenytoin, carbamazepine, dexamethasone, ketoconazole, erythromycin, anticoagulants.
Pregnancy
Positive evidence of risk: Avoid
Lactation
Contraindicated. Discontinue breast-feeding
Side Effects
Abdominal pain, alopecia, anorexia, arthralgia, bone-marrow suppression, cough, GI upset, dyspnea, epistaxis, fatigue, fistula formation (discontinue),GI perforation, hair& skin discoloration, hand-foot syndrome, headache, hepatic failure, hypertension, hyperuricaemia, hypothyroidism, increased lacrimation, insomnia, myalgia, oedema, oral mucositis, osteonecrosis of the jaw, pancreatitis, paraesthesia, peripheral neuropathy, proteinuria, rash, seizures, thromboembolism, tumourlysis syndrome, urine discoloration, vomiting. Rare: Nephrotic syndrome